Mesenchymal Stem Cell Therapy for Traumatic Brain Injury

Abstract

Traumatic brain injury (TBI) is a significant cause of death and disability in military and civilian populations. Cell therapy with mesenchymal stem cells (MSCs) shows promise for TBI. Because not all MSCs are equivalent, further work is needed to define optimal MSC products to minimize risk and maximize benefit. Here we proposed to establish a panel of assays to evaluate safety and potency of cell therapy products prior to administration. Assay results were used to select MSCs with different profiles for preclinical testing in rats. The maximal tolerated dose of MSCs will be determined in both uninjured and injured rats, and the distribution and retention of labeled cells following intravenous administration will be determined. MSC administration will be tested in rats subjected to TBI, and the impact of the cell therapy will be measured using a combination of histological, functional and behavioral testing.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2019
Accession Number
AD1094045

Entities

People

  • Barbara A Christy

Organizations

  • United States Army Institute of Surgical Research

Tags

DTIC Thesaurus Topics

  • Blood
  • Bone Marrow
  • Brain Injuries
  • Cells
  • Culture Techniques
  • Endothelial Cells
  • Fetus
  • Governments
  • Intercellular Junctions
  • Medical Personnel
  • Military Medicine
  • Professional Development
  • Stem Cells
  • Stromal Cells
  • Students
  • Test Methods
  • Therapy

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology and Pathology
  • Neurotrauma and Rehabilitation Medicine.
  • Toxicology/Environmental Toxicology

Technology Areas

  • Biotechnology